Logo
x

Search

Subscribe Now

small cell lung cancer

Disease of the Month – Small Cell Lung Cancer

Disease of the Month – Small Cell Lung Cancer

  • July 18, 2024
Takeda Entered into an Exclusive License Agreement with Puma Biotechnology for the Development and Commercialization of Alisertib

Takeda Entered into an Exclusive License Agreement with Puma Biotechnology for the Development and Commercialization of Alisertib

  • September 21, 2022
AstraZeneca Presents the Updated Results of Imfinzi (durvalumab) in P-III CASPIAN Trial for the Treatment of Extensive-Stage Small Cell Lung Cancer at ESMO 2021

AstraZeneca Presents the Updated Results of Imfinzi (durvalumab) in P-III CASPIAN Trial for the Treatment of Extensive-Stage Small...

  • September 20, 2021
AstraZeneca's Imfinzi (durvalumab) Receives NMPA's Approval as a 1L Treatment of Extensive-Stage Small Cell Lung Cancer

AstraZeneca's Imfinzi (durvalumab) Receives NMPA's Approval as a 1L Treatment of Extensive-Stage Small Cell Lung Cancer

  • July 19, 2021
G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

  • March 3, 2021
Jazz Pharma and PharmaMar's Zepzelca Fail to Meet its Primary Endpoint in P-III ATLANTIS Study for SCLC

Jazz Pharma and PharmaMar's Zepzelca Fail to Meet its Primary Endpoint in P-III ATLANTIS Study for SCLC

  • December 4, 2020
BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

    BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

    • October 4, 2024
    Henlius and Intas’ Hetronifly (Serplulimab) Receives the CHMP’s Positive Opinion to Treat Extensive-Stage SCLC

      Henlius and Intas’ Hetronifly (Serplulimab) Receives the CHMP’s Positive Opinion to Treat Extensive-Stage SCLC

      • September 21, 2024
      Merck and Daiichi Sankyo Report the P-III (HERTHENA-Lung02) Study Data of Patritumab Deruxtecan to Treat Non-Small Cell Lung Cancer

        Merck and Daiichi Sankyo Report the P-III (HERTHENA-Lung02) Study Data of Patritumab Deruxtecan to Treat Non-Small Cell Lung Cance...

        • September 17, 2024
        Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024

          Bayer Highlights New Results from the P-I/II Trial of BAY 2927088 for Non-Small Cell Lung Cancer at WCLC 2024

          • September 10, 2024
          Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

            Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

            • September 9, 2024
            Johnson & Johnson Reports New Long-Term Data from P-III (MARIPOSA) Trial of Rybrevant Plus Lazcluze for Advanced NSCLC

              Johnson & Johnson Reports New Long-Term Data from P-III (MARIPOSA) Trial of Rybrevant Plus Lazcluze for Advanced NSCLC

              • September 9, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.